Omeros Corp (NASDAQ: OMER) was upgraded by Zacks Investment Research from a “neutral” rating to an “outperform” rating in a research note issued to investors on Saturday.
Separately, analysts at Needham & Company reiterated a “hold” rating on shares of Omeros Corp in a research note to investors on Friday, January 6th. Analysts at Rodman & Renshaw upgraded shares of Omeros Corp from a “market perform” rating to an “outperform” rating in a research note to investors on Monday, December 5th. They now have a $13.00 price target on the stock. Also, analysts at Wedbush raised their price target on shares of Omeros Corp to $15.00 in a research note to investors on Wednesday, November 30th.
Omeros Corporation is a clinical-stage biopharmaceutical company. It is engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Its product candidates are derived from its PharmacoSurgerytm platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma. The Company has five ongoing clinical development programs, including four from its PharmacoSurgery platform and one from its Addiction program.
Omeros Corp opened at 5.59 on Friday. Omeros Corp has a 1-year low of $3.16 and a 1-year high of $8.00. The stock has a 50-day moving average of $4.40 and a 200-day moving average of $3.97. The company’s market cap is $125.0 million.